At-home DNA tests have become increasingly popular in recent years. But are they actually helpful for detecting cancer risk? In this post, learn about at-home DNA tests for cancer risk and why it’s always best to get genetic screening done through your health care provider.
Lung cancer survivor Amanda Nerstad shares what it was like receiving a stage 4 diagnosis at age 39, the role genomic testing played in prolonging her quality of life, and how she and her family cope with the diagnosis.
In this podcast, Dr. Funda Meric-Bernstam and Dr. Mark Robson discuss a new ASCO provisional clinical opinion on somatic genomic testing in people with metastatic or advanced cancer, including what it is and how it impacts cancer treatment.
In this post, Dr. Andrea Walens shares what it was like learning she had a genetic mutation that put her at an increased risk of breast cancer and why she decided to get a prophylactic double mastectomy to help prevent the development of cancer in the future.
Research from ASCO’s 2022 Genitourinary Cancers Symposium features a study on predicting the risk of developing and dying from metastatic prostate cancer in a diverse population.
In this podcast, 4 experts discuss the first-ever targeted therapies approved for people with non-small cell lung cancer with an epidermal growth factor receptor (EGFR) exon 20 insertion mutation, including how they work and what they mean for people with this type of cancer.
In this podcast, Dr. Brian Shuch and genetic counselor Lauren Bear discuss genetic conditions linked to kidney cancer, how they can impact people with kidney cancer and their families, and what to expect if you’re referred to meet with a genetic counselor.
Metastatic breast cancer survivor Marianne McNally describes how genomic testing and creating a game plan with her care team has allowed her to have a sense of control throughout her cancer experience.
In this article from The ASCO Post, Dr. Mark Lewis describes how his inherited cancer diagnosis has impacted his career as an oncologist and how it’s made him better able to empathize with his patients.
ASCO’s 2021 Advance of the Year highlights how progress in the treatment of gastrointestinal (GI) cancers is driven by molecular testing of tumors.
